Observation on the Effect of Anlotinib Combined with Concomitant Radiochemotherapy in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Objective:To explore the clinical effect of Anlotinib combined with concomitant radiochemotherapy(CCRT)in the treatment of locally advanced esophageal squamous cell carcinoma.Method:Clinical data of 80 patients with locally advanced esophageal squamous cell carcinoma treated in Liaocheng Infectious Disease Hospital from June 1,2021 to June 1,2022 were retrospectively analyzed,and divided into control group(n=38)and observation group(n=42)according to treatment regimen.The control group was treated with CCRT,and the observation group was treated with CCRT combined with Anlotinib.Progression free survival(PFS),overall survival(OS),disease control rate(DCR),objective response rate(ORR)and adverse events(AE)of the two groups were evaluated.Result:The ORR and DCR of observation group were 69.05%and 90.48%,respectively,which were significantly higher than 47.39%and 63.16%of control group,the differences were statistically significant(P<0.05).The median OS was 16 months[95%CI(14.484,17.516)]in the control group and 20 months[95%CI(15.585,24.415)]in the observation group,the difference between the two groups was statistically significant(x2=7.341,P=0.007).The median PFS was 15 months[95%CI(9.523,20.477)]in the control group and 20 months[95%CI(15.581,24.419)]in the observation group,the difference between the two groups was statistically significant(x2=12.844,P<0.001).There were no significant differences in the incidence of leucocytopenia,thrombocytopenia,anemia,gastrointestinal reaction,radiation esophagitis and cutaneous reaction between the two groups(P>0.05).The incidence of Ⅰ and Ⅱ grade hypertensive in observation group was significantly higher than that in control group(P<0.05).Conclusion:Anlotinib combined with CCRT in the treatment of locally advanced esophageal squamous cell carcinoma can improve the clinical efficacy,and prolong the survival time of patients.
国家科技期刊平台
NSTL
万方数据
